The different roles of ER subtypes in cancer biology and therapy

Nature Reviews Cancer

Volumn 11, Issue 8, 2011, Pages 597-608

  Thomas, Christoforos ^a   Gustafsson, Jan Åke ^a,b  

^a University of Houston   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DIETHYLSTILBESTROL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; GELDANAMYCIN; RADICICOL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER BIOLOGY; CANCER GENETICS; CANCER GROWTH; CANCER INVASION; CANCER THERAPY; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COLON CANCER; ENDOMETRIUM CANCER; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENETIC TRANSCRIPTION; HORMONE SUBSTITUTION; HUMAN; INTRADUCTAL CARCINOMA; LUNG CANCER; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANIMALS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HUMANS; NEOPLASMS; PROGNOSIS; PROTEIN ISOFORMS;

EID: 79960832381     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3093     Document Type: Review

References (188)

1. Heldring, N. et al. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 87, 905-931 (2007) (Pubitemid 47084672)
2. Toft, D. & Gorski, J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc. Natl Acad. Sci. USA 55, 1574-1581 (1966
3. Walter, P. et al. Cloning of the human estrogen receptor cDNA. Proc. Natl Acad. Sci. USA 82, 7889-7893 (1985 (Pubitemid 16179869)
4. Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S. & Gustafsson, J. A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA 93, 5925-5930 (1996) (Pubitemid 26190778)
5. Herynk, M. H. & Fuqua, S. A. Estrogen receptor mutations in human disease. Endocr. Rev. 25, 869-898 (2004) (Pubitemid 39657771)
6. Bjornstrom, L. & Sjoberg, M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 19, 833-842 (2005) (Pubitemid 40397050)
7. Colditz, G. A. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl Cancer Inst. 90, 814-823 (1998) (Pubitemid 28280547)
8. Hankinson, S. E., Colditz, G. A. & Willett, W. C. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 6, 213-218 (2004)
9. Shang, Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nature Rev. Cancer 6, 360-368 (2006)
10. Ellem, S. J. & Risbridger, G. P. Treating prostate cancer: a rationale for targeting local oestrogens. Nature Rev. Cancer 7, 621-627 (2007) (Pubitemid 47108185)
11. Fox, E. M., Davis, R. J. & Shupnik, M. A. ERβ in breast cancer-onlooker, passive player, or active protector? Steroids 73, 1039-1051 (2008)
12. Wong, N. A. et al. ERβ isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J. Pathol. 207, 53-60 (2005) (Pubitemid 41200714)
13. Musgrove, E. A. & Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nature Rev. Cancer 9, 631-643 (2009)
14. Speirs, V. et al. Clinical importance of estrogen receptor β isoforms in breast cancer. J. Clin. Oncol. 26, 5825-5826 (2008)
15. Stabile, L. P. et al. Combined analysis of estrogen receptor β-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin. Cancer Res. 17, 154-164 (2011)
16. Leung, Y. K. et al. Estrogen receptor β2 and β5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr. Relat. Cancer 17, 675-689 (2010)
17. Britton, D. J. et al. Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res. Treat 96, 131-146 (2006)
18. Nonclercq, D., Journe, F., Body, J. J., Leclercq, G. & Laurent, G. Ligand-independent and agonist-mediated degradation of estrogen receptor-α in breast carcinoma cells: evidence for distinct degradative pathways. Mol. Cell Endocrinol. 227, 53-65 (2004) (Pubitemid 39389124)
19. Swedenborg, E., Power, K. A., Cai, W., Pongratz, I. & Ruegg, J. Regulation of estrogen receptor β activity and implications in health and disease. Cell. Mol. Life Sci. 66, 3873-3894 (2009)
20. Xu, J., Wu, R. C. & O'Malley, B. W. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nature Rev. Cancer 9, 615-630 (2009)
21. Enmark, E. et al. Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J. Clin. Endocrinol. Metab. 82, 4258-4265 (1997 (Pubitemid 27525550)
22. Gosden, J. R., Middleton, P. G. & Rout, D. Localization of the human oestrogen receptor gene to chromosome 6q24-q27 by in situ hybridization. Cytogenet. Cell Genet. 43, 218-220 (1986 (Pubitemid 17234630)
23. Biswas, D. K., Singh, S., Shi, Q., Pardee, A. B. & Iglehart, J. D. Crossroads of estrogen receptor and NF-κB signaling. Sci. STKE 2005, pe27 (2005)
24. Fox, E. M., Andrade, J. & Shupnik, M. A. Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids 74, 622-627 (2009)
25. Carroll, J. S. et al. Genome-wide analysis of estrogen receptor binding sites. Nature Genet. 38, 1289-1297 (2006) (Pubitemid 44646291)
26. Menendez, D., Inga, A. & Resnick, M. A. Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences. Proc. Natl Acad. Sci. USA 107, 1500-1505 (2010)
27. Sotgia, F. et al. Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. Cancer Res. 66, 10647-10651 (2006) (Pubitemid 44876957)
28. Chambliss, K. L. et al. Estrogen receptor α and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ. Res. 87, e44-e52 (2000)
29. Kousteni, S. et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104, 719-730 (2001) (Pubitemid 32241022)
30. Massarweh, S. & Schiff, R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin. Cancer Res. 13, 1950-1954 (2007) (Pubitemid 46649859)
31. Razandi, M., Pedram, A., Merchenthaler, I., Greene, G. L. & Levin, E. R. Plasma membrane estrogen receptors exist and functions as dimers. Mol. Endocrinol. 18, 2854-2865 (2004) (Pubitemid 39577911)
32. Kahlert, S. et al. Estrogen receptor α rapidly activates the IGF-1 receptor pathway. J. Biol. Chem. 275, 18447-18453 (2000) (Pubitemid 30414803)
33. Shupnik, M. A. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 23, 7979-7989 (2004) (Pubitemid 39480682)
34. Song, R. X. et al. Linkage of rapid estrogen action to MAPK activation by ERα-Shc association and Shc pathway activation. Mol. Endocrinol. 16, 116-127 (2002) (Pubitemid 34044502)
35. Smith, C. L., Nawaz, Z. & O'Malley, B. W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11, 657-666 (1997 (Pubitemid 27225293)
36. Webb, P. et al. ERβ binds N-CoR in the presence of estrogens via an LXXLL-like motif in the N-CoR C-terminus. Nucl. Recept. 1, 4 (2003)
37. Bouras, T., Southey, M. C. & Venter, D. J. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res. 61, 903-907 (2001) (Pubitemid 32174400)
38. Klinge, C. M., Jernigan, S. C., Mattingly, K. A., Risinger, K. E. & Zhang, J. Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors α and β by coactivators and corepressors. J. Mol. Endocrinol. 33, 387-410 (2004) (Pubitemid 39429565)
39. Dubik, D. & Shiu, R. P. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7, 1587-1594 (1992
40. Hartman, J. et al. Tumor repressive functions of estrogen receptor β in SW480 colon cancer cells. Cancer Res. 69, 6100-6106 (2009)
41. Liu, M. M. et al. Opposing action of estrogen receptors α and β on cyclin D1 gene expression. J. Biol. Chem. 277, 24353-24360 (2002)
42. Foley, E. F., Jazaeri, A. A., Shupnik, M. A., Jazaeri, O. & Rice, L. W. Selective loss of estrogen receptor β in malignant human colon. Cancer Res. 60, 245-248 (2000) (Pubitemid 30070743)
43. Zhu, X. et al. Dynamic regulation of estrogen receptor-β expression by DNA methylation during prostate cancer development and metastasis. Am. J. Pathol. 164, 2003-2012 (2004) (Pubitemid 38669349)
44. Rutherford, T. et al. Absence of estrogen receptor-β expression in metastatic ovarian cancer. Obstet. Gynecol. 96, 417-421 (2000)
45. Leav, I. et al. Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 159, 79-92 (2001) (Pubitemid 33704195)
46. Eeckhoute, J. et al. Positive cross-regulatory loop ties GATA-3 to estrogen receptor α expression in breast cancer. Cancer Res. 67, 6477-6483 (2007) (Pubitemid 47037533)
47. Guo, S. & Sonenshein, G. E. Forkhead box transcription factor FOXO3a regulates estrogen receptor α expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol. Cell Biol. 24, 8681-8690 (2004) (Pubitemid 39245087)
48. Madureira, P. A. et al. The Forkhead box M1 protein regulates the transcription of the estrogen receptor α in breast cancer cells. J. Biol. Chem. 281, 25167-25176 (2006) (Pubitemid 44401903)
49. Adams, B. D., Furneaux, H. & White, B. A. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-α (ERα) and represses ERα messenger RNA and protein expression in breast cancer cell lines. Mol. Endocrinol. 21, 1132-1147 (2007) (Pubitemid 46984764)
50. Liu, W. H. et al. MicroRNA-18a prevents estrogen receptor-α expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 136, 683-693 (2009)
51. Zhao, J. J. et al. MicroRNA-221/222 negatively regulates estrogen receptor α and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 283, 31079-31086 (2008).
52. Al-Nakhle, H. et al. Estrogen receptor β1 expression is regulated by miR-92 in breast cancer. Cancer Res. 70, 4778-4784 (2010)
53. Pandey, D. P. & Picard, D. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor α mRNA. Mol. Cell Biol. 29, 3783-3790 (2009)
54. Richter, K. & Buchner, J. Hsp90: chaperoning signal transduction. J. Cell Physiol. 188, 281-290 (2001) (Pubitemid 32777169)
55. Duong, V. et al. Differential regulation of estrogen receptor α turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res. 67, 5513-5521 (2007) (Pubitemid 46997293)
56. Li, L., Li, Z., Howley, P. M. & Sacks, D. B. E6AP and calmodulin reciprocally regulate estrogen receptor stability. J. Biol. Chem. 281, 1978-1985 (2006) (Pubitemid 43845784)
57. Giamas, G. et al. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nature Med. 17, 715-719 (2011)
58. Pan, X. et al. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nature Med. 17, 708-714 (2011)
59. Bocchinfuso, W. P. & Korach, K. S. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J. Mammary Gland Biol. Neoplasia 2, 323-334 (1997
60. Korach, K. S. Insights from the study of animals lacking functional estrogen receptor. Science 266, 1524-1527 (1994
61. Feng, Y., Manka, D., Wagner, K. U. & Khan, S. A. Estrogen receptor-α expression in the mammary epithelium is required for ductal and alveolar morphogenesis in mice. Proc. Natl Acad. Sci. USA 104, 14718-14723 (2007) (Pubitemid 350003209)
62. Bocchinfuso, W. P., Hively, W. P., Couse, J. F., Varmus, H. E. & Korach, K. S. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-α. Cancer Res. 59, 1869-1876 (1999) (Pubitemid 29186159)
63. Hewitt, S. C. et al. Lack of ductal development in the absence of functional estrogen receptor α delays mammary tumor formation induced by transgenic expression of ErbB2/neu. Cancer Res. 62, 2798-2805 (2002) (Pubitemid 34525763)
64. Miermont, A. M., Parrish, A. R. & Furth, P. A. Role of ERα in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesis. Carcinogenesis 31, 1124-1131 (2010)
65. Yoshidome, K., Shibata, M. A., Couldrey, C., Korach, K. S. & Green, J. E. Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptorα expression during tumor progression. Cancer Res. 60, 6901-6910 (2000) (Pubitemid 32059162)
66. Risbridger, G. et al. Evidence that epithelial and mesenchymal estrogen receptor-α mediates effects of estrogen on prostatic epithelium. Dev. Biol. 229, 432-442 (2001) (Pubitemid 32108703)
67. Bianco, J. J., Handelsman, D. J., Pedersen, J. S. & Risbridger, G. P. Direct response of the murine prostate gland and seminal vesicles to estradiol. Endocrinology 143, 4922-4933 (2002) (Pubitemid 35397632)
68. Bianco, J. J., McPherson, S. J., Wang, H., Prins, G. S. & Risbridger, G. P. Transient neonatal estrogen exposure to estrogen-deficient mice (aromatase knockout) reduces prostate weight and induces inflammation in late life. Am. J. Pathol. 168, 1869-1878 (2006) (Pubitemid 43825307)
69. Prins, G. S. et al. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor α: studies with αERKO and βERKO mice. Cancer Res. 61, 6089-6097 (2001) (Pubitemid 32762544)
70. Gingrich, J. R. et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 56, 4096-4102 (1996) (Pubitemid 26304996)
71. Raghow, S., Hooshdaran, M. Z., Katiyar, S. & Steiner, M. S. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 62, 1370-1376 (2002) (Pubitemid 34407794)
72. Castro-Rivera, E., Samudio, I. & Safe, S. Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J. Biol. Chem. 276, 30853-30861 (2001)
73. List, H. J. et al. Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J. Biol. Chem. 276, 23763-23768 (2001)
74. Planas-Silva, M. D., Shang, Y., Donaher, J. L., Brown, M. & Weinberg, R. A. AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res. 61, 3858-3862 (2001) (Pubitemid 32720941)
75. Levin, E. R. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol. Endocrinol. 17, 309-317 (2003) (Pubitemid 36315626)
76. Driggers, P. H. & Segars, J. H. Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol. Metab. 13, 422-427 (2002)
77. Forster, C. et al. Involvement of estrogen receptor β in terminal differentiation of mammary gland epithelium. Proc. Natl Acad. Sci. USA 99, 15578-15583 (2002) (Pubitemid 35407484)
78. Imamov, O., Lopatkin, N. A. & Gustafsson, J. A. Estrogen receptor β in prostate cancer. N. Engl. J. Med. 351, 2773-2774 (2004)
79. Imamov, O. et al. Estrogen receptor β regulates epithelial cellular differentiation in the mouse ventral prostate. Proc. Natl Acad. Sci. USA 101, 9375-9380 (2004) (Pubitemid 38821066)
80. Weihua, Z. et al. A role for estrogen receptor β in the regulation of growth of the ventral prostate. Proc. Natl Acad. Sci. USA 98, 6330-6335 (2001) (Pubitemid 32492315)
81. Antal, M. C., Krust, A., Chambon, P. & Mark, M. Sterility and absence of histopathological defects in nonreproductive organs of a mouse ERβ-null mutant. Proc. Natl Acad. Sci. USA 105, 2433-2438 (2008) (Pubitemid 351520531)
82. Dupont, S. et al. Effect of single and compound knockouts of estrogen receptors α (ERα) and β (ERβ) on mouse reproductive phenotypes. Development 127, 4277-4291 (2000)
83. Nakajima, Y. et al. Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERβ and KLF5. Sci. Signal. 4, ra22 (2011)
84. Strom, A. et al. Estrogen receptor β inhibits 17β-estradiol- stimulated proliferation of the breast cancer cell line T47D. Proc. Natl Acad. Sci. USA 101, 1566-1571 (2004) (Pubitemid 38236167)
85. Lin, C. Y. et al. Inhibitory effects of estrogen receptor β on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res. 9, R25 (2007)
86. Lindberg, M. K. et al. Estrogen receptor (ER)-β reduces ERα-regulated gene transcription, supporting a "ying yang" relationship between ERα and ERβ in mice. Mol. Endocrinol. 17, 203-208 (2003) (Pubitemid 36187395)
87. Williams, C., Edvardsson, K., Lewandowski, S. A., Strom, A. & Gustafsson, J. A. A genome-wide study of the repressive effects of estrogen receptor β on estrogen receptor α signaling in breast cancer cells. Oncogene 27, 1019-1032 (2008) (Pubitemid 351225390)
88. Hartman, J. et al. Estrogen receptor β inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res. 66, 11207-11213 (2006) (Pubitemid 46009948)
89. Thomas, C. G., Strom, A., Lindberg, K. & Gustafsson, J. A. Estrogen receptor β decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling. Breast Cancer Res. Treat. 127, 417-427 (2011)
90. Hershberger, P. A. et al. Estrogen receptor β (ERβ) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J. Steroid Biochem. Mol. Biol. 116, 102-109 (2009)
91. Hou, Y. F. et al. ERβ exerts multiple stimulative effects on human breast carcinoma cells. Oncogene 23, 5799-5806 (2004)
92. Zhang, G. et al. Estrogen receptor β functions through nongenomic mechanisms in lung cancer cells. Mol. Endocrinol. 23, 146-156 (2009)
93. Mangelsdorf, D. J. et al. The nuclear receptor superfamily: the second decade. Cell 83, 835-839 (1995
94. Barone, I., Brusco, L. & Fuqua, S. A. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin. Cancer Res. 16, 2702-2708 (2010)
95. Lin, S. L. et al. ER-α36, a variant of ER-α, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS ONE 5, e9013 (2010)
96. Poola, I. & Speirs, V. Expression of alternatively spliced estrogen receptor α mRNAs is increased in breast cancer tissues. J. Steroid Biochem. Mol. Biol. 78, 459-469 (2001) (Pubitemid 34014827)
97. Poola, I., Koduri, S., Chatra, S. & Clarke, R. Identification of twenty alternatively spliced estrogen receptor α mRNAs in breast cancer cell lines and tumors using splice targeted primer approach. J. Steroid Biochem. Mol. Biol. 72, 249-258 (2000) (Pubitemid 30261529)
98. Shi, L. et al. Expression of ER-α36, a novel variant of estrogen receptor α, and resistance to tamoxifen treatment in breast cancer. J. Clin. Oncol. 27, 3423-3429 (2009)
99. Castles, C. G., Fuqua, S. A., Klotz, D. M. & Hill, S. M. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res. 53, 5934-5939 (1993 (Pubitemid 24006163)
100. Desai, A. J. et al. Presence of exon 5-deleted oestrogen receptor in human breast cancer: functional analysis and clinical significance. Br. J. Cancer 75, 1173-1184 (1997 (Pubitemid 27140030)
101. Erenburg, I., Schachter, B., Miray Lopez, R. & Ossowski, L. Loss of an estrogen receptor isoform (ER α δ 3) in breast cancer and the consequences of its reexpression: interference with estrogen-stimulated properties of malignant transformation. Mol. Endocrinol. 11, 2004-2015 (1997 (Pubitemid 27524883)
102. Moore, J. T. et al. Cloning and characterization of human estrogen receptor β isoforms. Biochem. Biophys. Res. Commun. 247, 75-78 (1998) (Pubitemid 28412528)
103. Omoto, Y., Eguchi, H., Yamamoto-Yamaguchi, Y. & Hayashi, S. Estrogen receptor (ER) β1 and ERβcx/β2 inhibit ERα function differently in breast cancer cell line MCF7. Oncogene 22, 5011-5020 (2003) (Pubitemid 37028337)
104. Peng, B., Lu, B., Leygue, E. & Murphy, L. C. Putative functional characteristics of human estrogen receptor-β isoforms. J. Mol. Endocrinol. 30, 13-29 (2003) (Pubitemid 36305253)
105. Green, C. A., Peter, M. B., Speirs, V. & Shaaban, A. M. The potential role of ER β isoforms in the clinical management of breast cancer. Histopathology 53, 374-380 (2008)
106. Shaaban, A. M. et al. Nuclear and cytoplasmic expression of ERβ1, ERβ2, and ERβ5 identifies distinct prognostic outcome for breast cancer patients. Clin. Cancer Res. 14, 5228-5235 (2008)
107. Saji, S. et al. Expression of estrogen receptor (ER) (β) cx protein in ER(α)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res. 62, 4849-4853 (2002) (Pubitemid 34984402)
108. Yan, M., Rayoo, M., Takano, E. A. & Fox, S. B. Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Res. Treat 126, 395-405 (2010)
109. Pettersson, K., Delaunay, F. & Gustafsson, J. A. Estrogen receptor β acts as a dominant regulator of estrogen signaling. Oncogene 19, 4970-4978 (2000)
110. Wang, X. et al. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nature Cell Biol. 9, 470-478 (2007) (Pubitemid 46511081)
111. Ye, Y. et al. ERα signaling through slug regulates E-cadherin and EMT. Oncogene 29, 1451-1462 (2010)
112. Mak, P. et al. ERβ impedes prostate cancer EMT by destabilizing HIF-1α and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 17, 319-332 (2010)
113. Helguero, L. A. et al. Different roles of estrogen receptors α and β in the regulation of E-cadherin protein levels in a mouse mammary epithelial cell line. Cancer Res. 68, 8695-8704 (2008)
114. Lindberg, K. et al. Expression of estrogen receptor β increases integrin α1 and integrin β1 levels and enhances adhesion of breast cancer cells. J. Cell Physiol. 222, 156-167 (2010)
115. Shaaban, A. M. et al. Declining estrogen receptor-β expression defines malignant progression of human breast neoplasia. Am. J. Surg. Pathol. 27, 1502-1512 (2003) (Pubitemid 37486611)
116. Skliris, G. P. et al. Reduced expression of oestrogen receptor β in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J. Pathol. 201, 213-220 (2003) (Pubitemid 37258932)
117. Leung, Y. K., Mak, P., Hassan, S. & Ho, S. M. Estrogen receptor (ER)-β isoforms: a key to understanding ER-β signaling. Proc. Natl Acad. Sci. USA 103, 13162-13167 (2006) (Pubitemid 44338933)
118. Boyd, S. Remarks on oophorectomy in the treatment of cancer of the breast. Br. Med. J. 1, 257-262 (1899
119. Bosland, M. C. et al. Chemoprevention strategies for prostate cancer. Eur. J. Cancer Prev. 11, S18-S27 (2002) (Pubitemid 35265859)
120. Couse, J. F. & Korach, K. S. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev. 20, 358-417 (1999) (Pubitemid 30654784)
121. Deroo, B. J. & Korach, K. S. Estrogen receptors and human disease. J. Clin. Invest. 116, 561-570 (2006) (Pubitemid 43326860)
122. Mah, V. et al. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res. 67, 10484-10490 (2007) (Pubitemid 350070824)
123. Henderson, B. E. & Feigelson, H. S. Hormonal carcinogenesis. Carcinogenesis 21, 427-433 (2000) (Pubitemid 30137927)
124. Jarred, R. A. et al. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol. Biomarkers Prev. 11, 1689-1696 (2002) (Pubitemid 36020026)
125. Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002) (Pubitemid 34761611)
126. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005)
127. Johnston, S. R. & Dowsett, M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nature Rev. Cancer 3, 821-831 (2003) (Pubitemid 37376980)
128. Smith, M. R. et al. Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. Cancer 95, 1864-1868 (2002) (Pubitemid 35222165)
129. Leygue, E., Dotzlaw, H., Watson, P. H. & Murphy, L. C. Altered estrogen receptor α and β messenger RNA expression during human breast tumorigenesis. Cancer Res. 58, 3197-3201 (1998) (Pubitemid 28371051)
130. Roger, P. et al. Dissociated overexpression of cathepsin D and estrogen receptor α in preinvasive mammary tumors. Hum. Pathol. 31, 593-600 (2000) (Pubitemid 30323985)
131. Chi, A., Chen, X., Chirala, M. & Younes, M. Differential expression of estrogen receptor β isoforms in human breast cancer tissue. Anticancer Res. 23, 211-216 (2003) (Pubitemid 36358520)
132. Esslimani-Sahla, M. et al. Increased estrogen receptor βcx expression during mammary carcinogenesis. Clin. Cancer Res. 11, 3170-3174 (2005) (Pubitemid 40637201)
133. Bonkhoff, H., Fixemer, T., Hunsicker, I. & Remberger, K. Progesterone receptor expression in human prostate cancer: correlation with tumor progression. Prostate 48, 285-291 (2001) (Pubitemid 32816554)
134. Hogdall, E. V. et al. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol. Rep. 18, 1051-1059 (2007)
135. Issa, R. M. et al. Estrogen receptor gene amplification occurs rarely in ovarian cancer. Mod. Pathol. 22, 191-196 (2009)
136. Jazaeri, A. A. et al. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene 20, 6965-6969 (2001) (Pubitemid 33052187)
137. Saegusa, M. & Okayasu, I. Changes in expression of estrogen receptors α and β in relation to progesterone receptor and pS2 status in normal and malignant endometrium. Jpn. J. Cancer Res. 91, 510-518 (2000) (Pubitemid 30392322)
138. Tan, D. S., Lambros, M. B., Marchio, C. & Reis-Filho, J. S. ESR1 amplification in endometrial carcinomas: hope or hyperbole? J. Pathol. 216, 271-274 (2008)
139. Critchley, H. O. et al. Wild-type estrogen receptor (ERβ1) and the splice variant (ERβcx/β2) are both expressed within the human endometrium throughout the normal menstrual cycle. J. Clin. Endocrinol. Metab. 87, 5265-5273 (2002) (Pubitemid 35316373)
140. Skrzypczak, M. et al. Evaluation of mRNA expression of estrogen receptor β and its isoforms in human normal and neoplastic endometrium. Int. J. Cancer 110, 783-787 (2004) (Pubitemid 38758502)
141. Suzuki, F. et al. Loss of estrogen receptor β isoform expression and its correlation with aberrant DNA methylation of the 5′-untranslated region in human epithelial ovarian carcinoma. Cancer Sci. 99, 2365-2372 (2008)
142. Jassam, N., Bell, S. M., Speirs, V. & Quirke, P. Loss of expression of oestrogen receptor β in colon cancer and its association with Dukes' staging. Oncol. Rep. 14, 17-21 (2005)
143. Shah, Y. M. & Rowan, B. G. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (α) promoter interaction and elevated steroid receptor coactivator 1 activity. Mol. Endocrinol. 19, 732-748 (2005) (Pubitemid 40349444)
144. Smith, C. L. & O'Malley, B. W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25, 45-71 (2004) (Pubitemid 38292038)
145. Picard, N. et al. Phosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor β. Mol. Endocrinol. 22, 317-330 (2008) (Pubitemid 351192911)
146. Sauve, K., Lepage, J., Sanchez, M., Heveker, N. & Tremblay, A. Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res. 69, 5793-5800 (2009)
147. Skliris, G. P. et al. Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor α (ERα) in tissue microarrays of ERα positive human breast carcinomas. Breast Cancer Res. Treat 118, 443-453 (2009)
148. Holm, C. et al. Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer. J. Pathol. 217, 372-379 (2009)
149. Kok, M. et al. Estrogen receptor-α phosphorylation at serine-118 and tamoxifen response in breast cancer. J. Natl Cancer Inst. 101, 1725-1729 (2009)
150. Murphy, L. et al. Phospho-serine-118 estrogen receptor-α detection in human breast tumors in vivo. Clin. Cancer Res. 10, 1354-1359 (2004). (Pubitemid 38365228)
151. Murphy, L. C., Niu, Y., Snell, L. & Watson, P. Phospho-serine-118 estrogen receptor-α expression is associated with better disease outcome in women treated with tamoxifen. Clin. Cancer Res. 10, 5902-5906 (2004). (Pubitemid 39180972)
152. Sarwar, N. et al. Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression. Endocr. Relat. Cancer 13, 851-861 (2006). (Pubitemid 44763261)
153. Yamashita, H. et al. Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res. 7, R753-R764 (2005).
154. Yamashita, H. et al. Low phosphorylation of estrogen receptor α (ERα) serine 118 and high phosphorylation of ERα serine 167 improve survival in ER-positive breast cancer. Endocr. Relat. Cancer 15, 755-763 (2008).
155. Hamilton-Burke, W. et al. Phosphorylation of estrogen receptor β at serine 105 is associated with good prognosis in breast cancer. Am. J. Pathol. 177, 1079-1086 (2010).
156. Platet, N., Cathiard, A. M., Gleizes, M. & Garcia, M. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit. Rev. Oncol. Hematol. 51, 55-67 (2004). (Pubitemid 38781751)
157. Butt, A. J., McNeil, C. M., Musgrove, E. A. & Sutherland, R. L. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr. Relat. Cancer 12, S47-S59 (2005). (Pubitemid 41395413)
158. Musgrove, E. A. et al. Identification of functional networks of estrogen-and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS ONE 3, e2987 (2008).
159. Nehra, R. et al. BCL2 and CASP8 regulation by NF-κB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and-resistant breast cancer cells. FASEB J. 24, 2040-2055 (2010).
160. Hurtado, A. et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456, U663-U693 (2008).
161. Ali, S. & Coombes, R. C. Endocrine-responsive breast cancer and strategies for combating resistance. Nature Rev. Cancer 2, 101-112 (2002). (Pubitemid 37328797)
162. Osborne, C. K. et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl Cancer Inst. 95, 353-361 (2003). (Pubitemid 36395255)
163. Ring, A. & Dowsett, M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 11, 643-658 (2004). (Pubitemid 40065543)
164. Ishii, Y. et al. Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a pro-apoptotic unfolded protein response. Clin. Cancer Res. 17, 2292 (2011)).
165. Scriven, P. et al. Activation and clinical significance of the unfolded protein response in breast cancer. Br. J. Cancer 101, 1692-1698 (2009).
166. Honma, N. et al. Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J. Clin. Oncol. 26, 3727-3734 (2008).
167. Novelli, F. et al. A divergent role for estrogen receptor-β in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res. 10, R74 (2008).
168. Horvath, G., Leser, G., Hahlin, M. & Henriksson, M. Exon deletions and variants of human estrogen receptor mRNA in endometrial hyperplasia and adenocarcinoma. Int. J. Gynecol. Cancer 10, 128-136 (2000). (Pubitemid 30351312)
169. Kawai, H. et al. Estrogen receptor α and β are prognostic factors in non-small cell lung cancer. Clin. Cancer Res. 11, 5084-5089 (2005). (Pubitemid 41003691)
170. Nose, N. et al. Association between estrogen receptor-β expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J. Clin. Oncol. 27, 411-417 (2009).
171. Nose, N., Uramoto, H., Iwata, T., Hanagiri, T. & Yasumoto, K. Expression of estrogen receptor β predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. Lung Cancer 71, 350-355 (2010).
172. Raso, M. G. et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin. Cancer Res. 15, 5359-5368 (2009).
173. Schwartz, A. G. et al. Nuclear estrogen receptor β in lung cancer: expression and survival differences by sex. Clin. Cancer Res. 11, 7280-7287 (2005). (Pubitemid 41507685)
174. Skov, B. G., Fischer, B. M. & Pappot, H. Oestrogen receptor β over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 59, 88-94 (2008).
175. Wu, C. T., Chang, Y. L., Shih, J. Y. & Lee, Y. C. The significance of estrogen receptor β in 301 surgically treated non-small cell lung cancers. J. Thorac. Cardiovasc. Surg. 130, 979-986 (2005).
176. Alonso, L. et al. Gonadotropin and steroid receptors as prognostic factors in advanced ovarian cancer: a retrospective study. Clin. Transl. Oncol. 11, 748-752 (2009).
177. Darb-Esfahani, S. et al. Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue. Endocr. Relat. Cancer 16, 1229-1239 (2009).
178. Faggad, A. et al. Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression. J. Pathol. 220, 382-391 (2010).
179. Zamagni, C. et al. Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. Endocr. Relat. Cancer 16, 1241-1249 (2009).
180. Burges, A. et al. Prognostic significance of estrogen receptor α and β expression in human serous carcinomas of the ovary. Arch. Gynecol. Obstet. 281, 511-517 (2010).
181. Shabani, N. et al. Prognostic significance of oestrogen receptor α (ERα) and β (ERβ), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur. J. Cancer 43, 2434-2444 (2007). (Pubitemid 350001248)
182. Suthipintawong, C., Wejaranayang, C. & Vipupinyo, C. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma. J. Med. Assoc. Thai 91, 1779-1784 (2008).
183. Barone, M. et al. Dietary-induced ERβ upregulation counteracts intestinal neoplasia development in intact male ApcMin/+ mice. Carcinogenesis 31, 269-274 (2010).
184. Giroux, V., Lemay, F., Bernatchez, G., Robitaille, Y. & Carrier, J. C. Estrogen receptor β deficiency enhances small intestinal tumorigenesis in ApcMin/+ mice. Int. J. Cancer 123, 303-311 (2008). (Pubitemid 351842014)
185. Martineti, V. et al. ERβ is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr. Relat. Cancer 12, 455-469 (2005). (Pubitemid 40896459)
186. Wilkins, H. R., Doucet, K., Duke, V., Morra, A. & Johnson, N. Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing c-myb protein, and decreasing transcription of the anti-apoptotic protein bcl-2. Tumour Biol. 31, 16-22 (2010).
187. Bardin, A. et al. Involvement of estrogen receptor β in ovarian carcinogenesis. Cancer Res. 64, 5861-5869 (2004). (Pubitemid 39095587)
188. Fan, X. et al. Gonadotropin-positive pituitary tumors accompanied by ovarian tumors in aging female ERβ-/-mice. Proc. Natl Acad. Sci. USA 107, 6453-6458 (2010).